Neuronix Submits NeuroAD Approval Application to FDA

Neuronix has submitted a de novo with the FDA along with the positive results from its Alzheimer’s therapeutic system study.

The study enrolled 131 patients at nine medical centers in the US and in Israel over a 12-week period.

The therapeutic system is an investigational device and is not available for sale in the U.S. — Cynthia Jessup